Grail’s Galleri test gets FDA panel vote but concerns remain

Even though the molecular and clinical genetics devices panel of the medical devices advisory committee for the U.S. FDA voted in favor of Grail Inc.’s Galleri multi-cancer early detection test, a number of concerns were raised over its safety, effectiveness and clinical benefits.